Home > News > Industry > Pharma News > Battling COVID-19: Sun...

Battling COVID-19: Sun Pharma evaluating potential of existing products

"We are evaluating the potential of some existing products which can be useful in Covid19 treatment. These include Nafamostat Mesilate and phyto- pharmaceutical,AQCH.Both these products are currently undergoing Phase-2 trials in India," he added.

By - Ruchika Sharma
Published On 2020-08-29 06:31 GMT   |   Update On 2020-08-29 06:31 GMT

New Delhi: The pharma industry is at the forefront of the battle against Covid-19 and has responded to this global challenge by ensuring the availability of medicines despite supply chain disruptions, Sun Pharmaceutical Industries Chairman Israel Makov said on Thursday. Clinical trials are being conducted to test the effectiveness of many existing medicines in treating symptoms of Covid-19,...

Login or Register to read the full article
Register Now

New Delhi: The pharma industry is at the forefront of the battle against Covid-19 and has responded to this global challenge by ensuring the availability of medicines despite supply chain disruptions, Sun Pharmaceutical Industries Chairman Israel Makov said on Thursday. Clinical trials are being conducted to test the effectiveness of many existing medicines in treating symptoms of Covid-19, he added while addressing the annual general meeting (AGM) of the company.

Some of the global pharmaceutical companies, as well as few Indian firms, have also initiated clinical trials for the development of a Covid-19 vaccine, Makov said.
"Sun Pharma has ensured adequate supplies of medicines to its customers across the world despite the supply chain disruptions and the lockdown restrictions in various countries," he added.
Changes at manufacturing facilities have been made to ensure productivity, as well as adherence to all safety and hygiene protocols.
The company is also leveraging IT technology tools to ensure business continuity and to facilitate work-from-home for many employees, Makov said.
"We are evaluating the potential of some existing products which can be useful in Covid19 treatment. These include Nafamostat Mesilate and the phyto-pharmaceutical, AQCH. Both these products are currently undergoing Phase-2 trials in India," he added.
As part of the company's corporate social responsibility, "we donated certain medicines useful in managing Covid-19 symptoms and hand sanitizers worth about Rs 250 million to support the Indian government's Covid-19 pandemic response," Makov said.
Sun Pharma has also arranged personal protective equipment kits, disinfectants and gloves to help fight the pandemic, he added.

Read also: COVID-19: Sun Pharma Launches FluGuard At Rs 35 Per Tablet In India

Tags:    
Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Desk Editor for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Justify dose and rationality: CDSCO Panel Tells Dr. Reddy's Lab on Sacubitril-Valsartan tablets 25 mg
"Safety is primary focus for all our vaccines": Covaxin-developer Bharat Biotech
Caplin Point gets Colombia nod for Softgel Capsules division
AstraZeneca concludes equity investment agreement with Cellectis
Alembic Pharma gets USFDA EIR for Panelav Oncology formulation facility
Cipla, Glenmark recall products from American market over manufacturing issues
Bharat Biotech International Gets CDSCO Panel Nod to Study Mycobacterium Tuberculosis Live Attenuated Vaccine
JnJ submits regulatory applications to EMA for Tremfya for treatment of patients with ulcerative colitis, Crohn's disease